November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
February 2020 in “Bulletin of Experimental Biology and Medicine” Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
December 2021 in “Black sea journal of health science” Valproic acid can cause a rare allergic reaction leading to fluid around the lungs and heart, which is treatable by changing medication.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
January 2016 in “INTAS POLIVET” Fipronil spray effectively treats ear mites in Persian cats.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
17 citations
,
June 2022 in “Frontiers in Nutrition” Fermented mushroom extract reduces intestinal inflammation in mice.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
8 citations
,
August 2022 in “Microorganisms” A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
39 citations
,
January 2008 in “World Journal of Gastroenterology” Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
8 citations
,
April 2022 in “International Journal of Environmental Research and Public Health” Most children with epilepsy on antiepileptic drugs experience side effects, especially those on multiple drugs, but these drugs help reduce seizures.
October 2009 in “Nature Reviews Urology”
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
April 2025 in “Suez Canal University Medical Journal” Valproic acid can rarely cause fluid buildup around the lungs and heart.
May 2024 in “International journal of medicine and psychology.” Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
January 2021 in “International Journal of Advanced Research in Medicine” Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
May 2023 in “Journal of contemporary medicine” Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.